# KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Balance Sheet

- Company: KYMERA THERAPEUTICS, INC. (KYMR)
- Period: As of 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001193125-26-436975
- Page: https://plicit.ai/financials/kymr/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/kymr-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,767,269,000 US dollars
- **Current assets**: 998,592,000 US dollars
- **Non-current assets**: 768,677,000 US dollars
- **Liabilities**: 152,742,000 US dollars
- **Current liabilities**: 89,723,000 US dollars
- **Non-current liabilities**: 63,019,000 US dollars
- **Equity**: 1,614,527,000 US dollars
- **Marketable securities (Note 4)**: 597,840,000 US dollars
- **Cash and cash equivalents**: 373,374,000 US dollars
- **Prepaid expenses and other current assets**: 27,378,000 US dollars
- **Marketable securities, non-current (Note 4)**: 674,669,000 US dollars
- **Right-of-use assets, operating leases**: 40,444,000 US dollars
- **Property and equipment, net (Note 6)**: 38,242,000 US dollars
- **Other non-current assets**: 9,113,000 US dollars
- **Restricted cash**: 6,209,000 US dollars
- **Accrued expenses (Note 8)**: 63,315,000 US dollars
- **Operating lease liabilities**: 12,209,000 US dollars
- **Accounts payable**: 11,923,000 US dollars
- **Finance lease liabilities**: 1,371,000 US dollars
- **Other current liabilities**: 905,000 US dollars
- **Deferred revenue**: 0 US dollars
- **Operating lease liabilities, net of current portion**: 62,417,000 US dollars
- **Finance lease liabilities, net of current portion**: 602,000 US dollars
- **Deferred revenue, net of current portion**: 0 US dollars
- **Additional paid-in capital**: 2,957,658,000 US dollars
- **Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, 85,325,503 and 81,323,532 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively**: 9,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 1,328,405,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 14,735,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.
